23195-62-2

Usage

Uses

Used in Medicinal Chemistry:
2-(1H-1,2,4-triazol-3-yl)pyridine(SALTDATA: FREE) is utilized as a building block in the synthesis of pharmaceutical drugs and agrochemicals, leveraging its unique structure to create novel compounds with therapeutic or pesticidal properties.
Used in Antimicrobial Agents Development:
In the field of antimicrobial research, 2-(1H-1,2,4-triazol-3-yl)pyridine(SALTDATA: FREE) is studied for its potential antifungal and antibacterial properties, making it a promising candidate for the development of new antimicrobial agents to combat resistant strains of pathogens.
Used in Drug Synthesis:
2-(1H-1,2,4-triazol-3-yl)pyridine(SALTDATA: FREE) is employed as a key intermediate in the synthesis of various biologically active compounds, contributing to the discovery and creation of new drugs with potential applications in treating a range of diseases and conditions.

Upstream product

• 100-70-9 2-Cyanopyridine 
• 64-18-6 formic acid 
• 83507-07-7 N-(4'-quinazolon-3'-yl)-2-pyridinecarboxamidine 
• 54754-52-8 N-(2'-aminobenzoyl)-2-pyridylamidrazone 
• 5394-18-3 2-(4-bromobutyl)isoindoline-1,3-dione 
• 624-84-0 formic acid hydrazide 
• 20251-42-7 2-Pyridinecarbaldehyde oxime O-methyl ether 
• 1005-02-3 picolinamidrazone 

Relevant academic research and scientific papers

Synthesis, crystal structure and magnetic properties of new copper(II) complexes based on 3-(2-pyridyl)-1,2,4-triazole

The synthesis, crystal structure, spectroscopic and magnetic properties of binuclear [Cu2(L)2(SO4)(H2O)3]·3H2O (4a) and tetranuclear [Cu4(HL)2(L)4(DMF)2(SO4)2]·DMF (4b) copper(II) complexes were reported (where HL is 3-(pyridine-2-yl)-1,2,4-triazole). Potentiometric titrations, ESI-MS and spectrophotometric studies of complex formation in MeOH/H2O solutions indicated the presence of monomeric [CuHL]2+, dinuclear [Cu2L2]2+ and [Cu2L2(OH)]+, and trinuclear [Cu2L3]+ and [Cu2L3(OH)] species. The small N,N-nucleating ligand HL leads to a supramolecular formation of the complexes. The ligand comprises a triazole moiety substituted by pyridine group, strategically located to form chelate metalocycles. The basis of both complexes is two metal centres bridged via N1–N2 diazine grouping of a triazole ring. For complex 4b two HL coordinate in acidoform via NPy and N4 of azole moiety as well. There are significant differences in the polyhedrons, namely nuclearity and Cu…Cu separations. Complexes were characterized by elemental analysis, mass-spectrometry, IR- spectroscopy and X-ray analysis. Magnetic measurements revealed that both compounds exhibit antiferromagnetic interaction. The magnetic susceptibility data were interpreted on the basis of the spin Hamiltonian in the temperature range (2–300 K) using the dinuclear (4a: J1 = ?52.41 cm?1) and tetranuclear (4b: J1 = ?53.10 cm?1 to J2 = ?0.14 cm?1) models.

Synthesis, structure, and magnetic properties of a tris[3-(2-pyridyl)-1,2,4-triazole]iron(II) spin-crossover complex

The synthesis and characterization of tris[3-(pyridin-2-yl)-1,2,4-triazole]iron(II) bis(tetrafluoroborate), obtained from the reaction of 3-(pyridin-2-y1)-1,2,4-triazole (Hpt) and hexa-aquairon(II) tetrafluoroborate, [Fe(H2O)6](BF4)2, is described, together with its crystal structures at two temperatures. X-ray crystallographic parameters are as follows: [Fe(Hpt)3](BF4)2·nH2O (n ? 2) at 250 K: orthorhombic space group Pbam, a = 15.8068(18) A, b = 17.2800(14) A, c = 21.215(2) A, V = 5794.7(10) A3, and Z = 8. [Fe(Hpt)3](BF4)2·nH2O (n ? 2) at 95 K: orthorhombic space group Pbam, a = 15.7080(12) A, b = 17.1023(16) A, c = 21.006(2) A, V = 5643.1(9) A3, and Z = 8. The Fe(II) ions are (at both temperatures) octahedrally surrounded in a mer-configuration. The complex has been subjected to both 57Fe Mossbauer spectroscopy and magnetic susceptibility measurements. The 57Fe Mossbauer spectrum shows the presence of two different iron(II) sites. The high-spin fraction vs. T curve of the crossover, obtained by SQUID measurements, is gradual and without hysteresis, with T 1/2 = 135 K.

Structural and Electronic Properties of Iron(II) Complexes of 2-(1,2,4-Triazol-3-yl)pyridine and Substituted Derivatives

Iron(II) and nickel(II) tris(ligand) complexes of 2-(triazol-3-yl)pyridine and the substituted derivatives 2-(1(N)-methyltriazol-3-yl)pyridine and 2-(1,5-dimethyltriazol-3-yl)pyridine have been prepared.Coordination of the dimethyl-substituted ligand via N(4) of the triazolyl moieties is confirmed by structure determination of 2, which has the mer configuration.Tris(2-(1,5-dimethyltriazol-3-yl)pyridine)iron(II) bis(tetrafluoroborate): orthorhombic, space group Pbca, a 11.568(3), b 19.442(4), c 30.551(8) Angstroem, Z 8.The methyl substituents appear to have only a minor influence on the donor properties of the ligands, all three of which have field strengths in the iron(II) quintet singlet crossover region.Temperature-induced singlet quintet transitions occur in salts of the (2+) derivatives in both the solid and solution states.Moessbauer effect studies reveal the complexity of the solid state properties of salts of the iron complex of 2-(1(N)-methyltriazol-3-yl)pyridine and suggest that there is a fundamental change with time in the geometry of the complex cation.The metastable form of the complex hexafluorophosphate salt shows virtually no quadrupole splitting in the spectrum for the quintet state species, which implies high symmetry for the metal ion environment.Moessbauer studies further reveal the presence of multiple iron(II) sites in the lattice for salts containing either the N-methyl or the unsubstituted ligand.

Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase

Herein we describe the application of fragment-based drug design to bacterial DNA ligase. X-ray crystallography was used to guide structure-based optimization of a fragment-screening hit to give novel, nanomolar, AMP-competitive inhibitors. The lead compound 13 showed antibacterial activity across a range of pathogens. Data to demonstrate mode of action was provided using a strain of S. aureus, engineered to overexpress DNA ligase.

Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity

The highly potent, selective, and brain-penetrant metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 3-(5-pyridin-2-yl-2H-tetrazol-2-yl) benzonitrile (47) and 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (48) are reported. Compound 47 is active in the rat fear-potentiated startle (FPS) model of anxiety with ED50 = 5.4 mg/kg (po) when dosed acutely. In this model the anxiolytic effects of 47 rapidly tolerate on repeated dosing.

Erythromycin compounds

An erythromycin compound of Formula I or its non-toxic acid addition salt having antibiotic activity.

A SYNTHESIS OF N-(4'-QUINAZOLON-3'-YL)-2-PYRIDINECARBOXAMIDYNES AND THEIR CONVERSION INTO 1,2,4,TRIAZOLES

Treatment of N-(2'-aminobenzoyl)-2-pyrydilamidrazone (1) with ethoxymethylenemalononitrile (EMNN) and ethyl ethoxymethylenecyanoacetate (EMCA) or ortho esters afforded the corresponding N-(2'-alkyl-4'-quinazolon-3'-yl)-2-pyridinecarboxamides (2).Furthermore, treatment of 2 with ethanolic hydrochloric acid caused the ring transformation to give corresponding 5-alkyl-3-(2'-pyridyl)-1H-1,2,4-triazoles (3).